[Skip to Content]
[Skip to Content Landing]
Views 551
Citations 0
Lab Reports
April 5, 2016

Compound Reverses Memory Deficits in Model of Schizophrenia

JAMA. 2016;315(13):1327. doi:10.1001/jama.2016.2507

New research in mice suggests that memory deficits caused by a 22q11.2 microdeletion, which is the single largest genetic risk factor for schizophrenia, can be treated with antagonists of the glycogen synthase kinase 3 β (Gsk3β) protein (Tamura M et al. Neuron. doi:10.1016/j.neuron.2016.01.025 [published online February 18, 2016]). Gsk3β is involved in energy metabolism, neuronal cell development, and body pattern formation.

First Page Preview View Large
First page PDF preview
First page PDF preview